Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.
2.

Vitamin E reduces cardiovascular disease in individuals with diabetes mellitus and the haptoglobin 2-2 genotype.

Blum S, Vardi M, Brown JB, Russell A, Milman U, Shapira C, Levy NS, Miller-Lotan R, Asleh R, Levy AP.

Pharmacogenomics. 2010 May;11(5):675-84. doi: 10.2217/pgs.10.17.

3.

Vitamin E supplementation reduces cardiovascular events in a subgroup of middle-aged individuals with both type 2 diabetes mellitus and the haptoglobin 2-2 genotype: a prospective double-blinded clinical trial.

Milman U, Blum S, Shapira C, Aronson D, Miller-Lotan R, Anbinder Y, Alshiek J, Bennett L, Kostenko M, Landau M, Keidar S, Levy Y, Khemlin A, Radan A, Levy AP.

Arterioscler Thromb Vasc Biol. 2008 Feb;28(2):341-7. Epub 2007 Nov 21.

4.

Patient selection and vitamin E treatment in diabetes mellitus.

Goldenstein H, Levy NS, Lipener YT, Levy AP.

Expert Rev Cardiovasc Ther. 2013 Mar;11(3):319-26. doi: 10.1586/erc.12.187. Review.

5.
6.

Correction of HDL dysfunction in individuals with diabetes and the haptoglobin 2-2 genotype.

Asleh R, Blum S, Kalet-Litman S, Alshiek J, Miller-Lotan R, Asaf R, Rock W, Aviram M, Milman U, Shapira C, Abassi Z, Levy AP.

Diabetes. 2008 Oct;57(10):2794-800. doi: 10.2337/db08-0450. Epub 2008 Jul 3.

7.

Pharmacogenomic application of the haptoglobin genotype in the prevention of diabetic cardiovascular disease.

Blum S, Milman U, Shapira C, Levy AP.

Pharmacogenomics. 2008 Aug;9(8):989-91. doi: 10.2217/14622416.9.8.989. No abstract available.

8.
9.

Haptoglobin: a major susceptibility gene for diabetic cardiovascular disease.

Levy AP.

Isr Med Assoc J. 2004 May;6(5):308-10. Review. No abstract available.

10.

Interaction Between the Haptoglobin Genotype and Vitamin E on Cardiovascular Disease in Diabetes.

Hochberg I, Berinstein EM, Milman U, Shapira C, Levy AP.

Curr Diab Rep. 2017 Jun;17(6):42. doi: 10.1007/s11892-017-0868-1. Review.

PMID:
28451949
11.

Haptoglobin 2-2 genotype is not associated with cardiovascular risk in subjects with elevated glycohemoglobin-results from the Bruneck Study.

Pechlaner R, Kiechl S, Willeit P, Demetz E, Haun M, Weger S, Oberhollenzer F, Kronenberg F, Bonora E, Weiss G, Willeit J.

J Am Heart Assoc. 2014 May 16;3(3):e000732. doi: 10.1161/JAHA.113.000732.

12.

Vitamin E in the prevention of cardiovascular disease: the importance of proper patient selection.

Vardi M, Levy NS, Levy AP.

J Lipid Res. 2013 Sep;54(9):2307-14. doi: 10.1194/jlr.R026641. Epub 2013 Mar 15. Review.

13.

Antioxidants in the prevention of atherosclerosis: the importance of proper patient selection.

Levy Y, Blum S, Levy AP.

Clin Nutr. 2009 Oct;28(5):581-2. doi: 10.1016/j.clnu.2009.04.012. Epub 2009 May 22.

PMID:
19464773
14.

Effect of vitamin E supplementation on HDL function by haptoglobin genotype in type 1 diabetes: results from the HapE randomized crossover pilot trial.

Costacou T, Levy AP, Miller RG, Snell-Bergeon J, Asleh R, Farbstein D, Fickley CE, Pambianco G, de la Vega R, Evans RW, Orchard TJ.

Acta Diabetol. 2016 Apr;53(2):243-50. doi: 10.1007/s00592-015-0770-8. Epub 2015 May 24.

15.

Haptoglobin phenotype, pre-eclampsia, and response to supplementation with vitamins C and E in pregnant women with type-1 diabetes.

Weissgerber TL, Gandley RE, Roberts JM, Patterson CC, Holmes VA, Young IS, McCance DR; Diabetes and Pre-eclampsia Intervention Trial (DAPIT) Study Group.

BJOG. 2013 Sep;120(10):1192-9. doi: 10.1111/1471-0528.12288. Epub 2013 May 30.

16.

Pharmacogenomic effect of vitamin E on kidney structure and function in transgenic mice with the haptoglobin 2-2 genotype and diabetes mellitus.

Nakhoul FM, Miller-Lotan R, Awad H, Asleh R, Jad K, Nakhoul N, Asaf R, Abu-Saleh N, Levy AP.

Am J Physiol Renal Physiol. 2009 Apr;296(4):F830-8. doi: 10.1152/ajprenal.90655.2008. Epub 2009 Jan 28.

PMID:
19176700
17.

The effect of vitamin E supplementation on cardiovascular risk in diabetic individuals with different haptoglobin phenotypes.

Levy AP, Gerstein HC, Miller-Lotan R, Ratner R, McQueen M, Lonn E, Pogue J.

Diabetes Care. 2004 Nov;27(11):2767. No abstract available.

PMID:
15505023
18.

The effect of vitamin E supplementation on cardiovascular risk in diabetic individuals with different haptoglobin phenotypes.

Blum S, Vardi M, Levy NS, Miller-Lotan R, Levy AP.

Atherosclerosis. 2010 Jul;211(1):25-7. doi: 10.1016/j.atherosclerosis.2010.02.018. Epub 2010 Feb 21. No abstract available.

19.

Vitamin E therapy results in a reduction in HDL function in individuals with diabetes and the haptoglobin 2-1 genotype.

Farbstein D, Blum S, Pollak M, Asaf R, Viener HL, Lache O, Asleh R, Miller-Lotan R, Barkay I, Star M, Schwartz A, Kalet-Littman S, Ozeri D, Vaya J, Tavori H, Vardi M, Laor A, Bucher SE, Anbinder Y, Moskovich D, Abbas N, Perry N, Levy Y, Levy AP.

Atherosclerosis. 2011 Nov;219(1):240-4. doi: 10.1016/j.atherosclerosis.2011.06.005. Epub 2011 Jun 13.

20.

Haptoglobin phenotype, preeclampsia risk and the efficacy of vitamin C and E supplementation to prevent preeclampsia in a racially diverse population.

Weissgerber TL, Gandley RE, McGee PL, Spong CY, Myatt L, Leveno KJ, Thorp JM Jr, Mercer BM, Peaceman AM, Ramin SM, Carpenter MW, Samuels P, Sciscione A, Harper M, Tolosa JE, Saade G, Sorokin Y; Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network.

PLoS One. 2013;8(4):e60479. doi: 10.1371/journal.pone.0060479. Epub 2013 Apr 3.

Supplemental Content

Support Center